SOURCE: Innoviva, Inc.

Innoviva, Inc.

March 01, 2016 16:05 ET

Innoviva to Present at the Cowen & Company 36th Annual Health Care Conference 2016

SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 1, 2016) -  Innoviva, Inc. (NASDAQ: INVA) announced today that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, is scheduled to present at the Cowen & Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:40 a.m. EST. The conference will be held from March 7-9, 2016 in Boston, MA.

The presentation will be webcast live and can be accessed from Innoviva's website at www.inva.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

About Innoviva
Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)

Contact Information